Select Your Region
Americas
Europe
Africa
Global
Find participating medical centers and current study status in each of them
Find participating medical centers
-
Home
-
Clinical Study Finder
- IPATential150
Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Cancer Prostate Cancer Metastatic Prostate Cancer
Study results
LPS CO39303 IPATential150 Interim Results June 2021 English
(PDF, 0.7 MB)
LPS CO39303 IPATential150 Interim Results August 2021 Korea Korean
(PDF, 1.2 MB)
LPS CO39303 IPATential150 Interim Results August 2021 Norway Norwegian
(PDF, 0.7 MB)
LPS CO39303 IPATential150 Interim Results June 2021 Austria German
(PDF, 0.3 MB)
LPS CO39303 IPATential150 Interim Results June 2021 Belgium French Dutch
(PDF, 0.3 MB)
LPS CO39303 IPATential150 Interim Results June 2021 Brazil Portugese
(PDF, 0.4 MB)
LPS CO39303 IPATential150 Interim Results June 2021 Canada French
(PDF, 0.4 MB)
LPS CO39303 IPATential150 Interim Results June 2021 Costa Rica Spanish
(PDF, 0.3 MB)
LPS CO39303 IPATential150 Interim Results June 2021 Denmark Danish
(PDF, 0.3 MB)
LPS CO39303 IPATential150 Interim Results June 2021 Hungary Hungarian
(PDF, 0.4 MB)
LPS CO39303 IPATential150 Interim Results June 2021 Israel Hebrew
(PDF, 0.7 MB)
LPS CO39303 IPATential150 Interim Results June 2021 Italy Italian
(PDF, 0.8 MB)
LPS CO39303 IPATential150 Interim Results June 2021 Mexico Spanish
(PDF, 0.4 MB)
LPS CO39303 IPATential150 Interim Results June 2021 Poland Polish
(PDF, 0.3 MB)
LPS CO39303 IPATential150 Interim Results June 2021 Russia Russian
(PDF, 0.4 MB)
LPS CO39303 IPATential150 Interim Results June 2021 Spain Spanish
(PDF, 0.7 MB)
LPS CO39303 IPATential150 Interim Results June 2021 Taiwan Chinese
(PDF, 1.0 MB)
LPS CO39303 IPATential150 Interim Results November 2021 Portugal Portuguese
(PDF, 0.3 MB)
LPS CO39303 IPATential150 Final Results December 2024 English
(PDF, 0.7 MB)
LPS CO39303 IPATential150 Final Results December 2024 Austria German
(PDF, 0.8 MB)
LPS CO39303 IPATential150 Final Results December 2024 Belgium Dutch
(PDF, 0.5 MB)
LPS CO39303 IPATential150 Final Results December 2024 Belgium French
(PDF, 0.5 MB)
LPS CO39303 IPATential150 Final Results December 2024 Brazil Portuguese
(PDF, 0.4 MB)
LPS CO39303 IPATential150 Final Results December 2024 Canada French
(PDF, 0.7 MB)
LPS CO39303 IPATential150 Final Results December 2024 Costa Rica Spanish
(PDF, 0.5 MB)
LPS CO39303 IPATential150 Final Results December 2024 Danish
(PDF, 0.6 MB)
LPS CO39303 IPATential150 Final Results December 2024 France French
(PDF, 0.9 MB)
LPS CO39303 IPATential150 Final Results December 2024 Greek
(PDF, 1.2 MB)
LPS CO39303 IPATential150 Final Results December 2024 Hungarian
(PDF, 0.7 MB)
LPS CO39303 IPATential150 Final Results December 2024 Italian
(PDF, 0.6 MB)
LPS CO39303 IPATential150 Final Results December 2024 Mexico Spanish
(PDF, 0.6 MB)
LPS CO39303 IPATential150 Final Results December 2024 Polish
(PDF, 0.9 MB)
LPS CO39303 IPATential150 Final Results December 2024 Russia Russian
(PDF, 0.8 MB)
LPS CO39303 IPATential150 Final Results December 2024 Spain Spanish
(PDF, 0.5 MB)
LPS CO39303 IPATential150 Final Results February 2025 Australia English
(PDF, 1.3 MB)
LPS CO39303 IPATential150 Final Results February 2025 Israel Hebrew
(PDF, 1.3 MB)
LPS CO39303 IPATential150 Final Results February 2025 Taiwan Chinese
(PDF, 0.4 MB)
LPS CO39303 IPATential150 Final Results March 2025 Israel Arabic
(PDF, 1.4 MB)
LPS CO39303 IPATential150 Final Results March 2025 Israel Russian
(PDF, 1.2 MB)
LPS CO39303 IPATential150 Final Results December 2024 Norwegian
(PDF, 0.3 MB)
Explore related studies
For the latest version of this information please go to www.forpatients.roche.com